Free Trial

LENZ Therapeutics (LENZ) Competitors

LENZ Therapeutics logo
$31.62 -1.78 (-5.33%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$31.86 +0.23 (+0.74%)
As of 07/25/2025 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LENZ vs. ACAD, PTCT, ZLAB, ACLX, VKTX, SWTX, AAPG, PTGX, MLTX, and HCM

Should you be buying LENZ Therapeutics stock or one of its competitors? The main competitors of LENZ Therapeutics include ACADIA Pharmaceuticals (ACAD), PTC Therapeutics (PTCT), Zai Lab (ZLAB), Arcellx (ACLX), Viking Therapeutics (VKTX), SpringWorks Therapeutics (SWTX), Ascentage Pharma Group International (AAPG), Protagonist Therapeutics (PTGX), MoonLake Immunotherapeutics (MLTX), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry.

LENZ Therapeutics vs. Its Competitors

ACADIA Pharmaceuticals (NASDAQ:ACAD) and LENZ Therapeutics (NASDAQ:LENZ) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 26.5% of ACADIA Pharmaceuticals shares are held by company insiders. Comparatively, 6.9% of LENZ Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ACADIA Pharmaceuticals has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ACADIA Pharmaceuticals$957.80M4.06$226.45M$1.3716.97
LENZ TherapeuticsN/AN/A-$49.77M-$1.77-17.86

ACADIA Pharmaceuticals presently has a consensus price target of $28.13, indicating a potential upside of 20.97%. LENZ Therapeutics has a consensus price target of $46.60, indicating a potential upside of 47.38%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe LENZ Therapeutics is more favorable than ACADIA Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ACADIA Pharmaceuticals
0 Sell rating(s)
6 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.71
LENZ Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17

ACADIA Pharmaceuticals has a net margin of 22.97% compared to LENZ Therapeutics' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 17.46% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ACADIA Pharmaceuticals22.97% 17.46% 10.75%
LENZ Therapeutics N/A -23.74%-22.65%

In the previous week, ACADIA Pharmaceuticals had 8 more articles in the media than LENZ Therapeutics. MarketBeat recorded 12 mentions for ACADIA Pharmaceuticals and 4 mentions for LENZ Therapeutics. ACADIA Pharmaceuticals' average media sentiment score of 1.20 beat LENZ Therapeutics' score of 1.13 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ACADIA Pharmaceuticals
7 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
LENZ Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ACADIA Pharmaceuticals has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500.

Summary

ACADIA Pharmaceuticals beats LENZ Therapeutics on 13 of the 15 factors compared between the two stocks.

Get LENZ Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LENZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LENZ vs. The Competition

MetricLENZ TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$940.08M$3.07B$5.70B$9.50B
Dividend YieldN/A2.37%4.69%4.01%
P/E Ratio-17.8621.1828.1020.06
Price / SalesN/A283.55428.7189.11
Price / CashN/A42.7636.2258.56
Price / Book4.268.378.665.87
Net Income-$49.77M-$55.19M$3.25B$258.55M
7 Day Performance-6.26%5.88%4.22%3.73%
1 Month Performance5.01%17.33%10.51%11.75%
1 Year Performance31.91%4.42%34.40%18.02%

LENZ Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LENZ
LENZ Therapeutics
1.5609 of 5 stars
$31.62
-5.3%
$46.60
+47.4%
+31.4%$940.08MN/A-17.86110News Coverage
Gap Up
ACAD
ACADIA Pharmaceuticals
4.2562 of 5 stars
$22.28
-1.2%
$27.88
+25.1%
+25.3%$3.78B$996.28M16.26510Positive News
Analyst Forecast
PTCT
PTC Therapeutics
4.4327 of 5 stars
$47.86
+0.5%
$65.00
+35.8%
+33.3%$3.78B$1.77B7.351,410News Coverage
Positive News
ZLAB
Zai Lab
3.1865 of 5 stars
$34.66
+3.2%
$54.28
+56.6%
+97.0%$3.73B$398.99M-13.921,869Positive News
Gap Up
ACLX
Arcellx
2.3525 of 5 stars
$69.39
+2.7%
$111.23
+60.3%
+13.8%$3.72B$107.94M-23.2180News Coverage
Positive News
VKTX
Viking Therapeutics
4.8503 of 5 stars
$31.94
-0.2%
$87.15
+172.9%
-46.8%$3.60BN/A-27.7720Trending News
Earnings Report
Analyst Forecast
Analyst Revision
SWTX
SpringWorks Therapeutics
1.349 of 5 stars
$46.99
flat
$52.57
+11.9%
N/A$3.54B$191.59M-13.78230
AAPG
Ascentage Pharma Group International
N/A$39.71
-1.7%
N/AN/A$3.52B$134.35M0.00600Lockup Expiration
Gap Down
PTGX
Protagonist Therapeutics
1.381 of 5 stars
$55.22
-0.5%
$66.10
+19.7%
+32.7%$3.44B$434.43M73.63120News Coverage
Insider Trade
MLTX
MoonLake Immunotherapeutics
2.1665 of 5 stars
$53.57
+0.9%
$74.50
+39.1%
+22.6%$3.40BN/A-23.292News Coverage
Options Volume
HCM
HUTCHMED
2.7604 of 5 stars
$17.74
+0.9%
$19.00
+7.1%
-2.2%$3.07B$630.20M0.001,811Analyst Forecast

Related Companies and Tools


This page (NASDAQ:LENZ) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners